GE HealthCare (GEHC) reported total revenues of $5.1 billion for the first quarter of 2026 (ended March 31), up 7.4% year-over-year, driven by strength in its Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging segments.
The company’s net income fell to $389 million from $564 million in the prior-year period, however, while adjusted EBIT dropped to $691 million from $715 million. Both measures were negatively affected by tariffs, a decline in the Patient Care Solutions segment, and “a discrete PDx supplier issue” that has since been resolved, the company said.
On a segment basis, Pharmaceutical Diagnostics led growth with revenues up 21.7% to $770 million, driven in part by Flyrcado, the company’s PET myocardial perfusion imaging agent. Advanced Visualization Solutions revenues rose 8.2% to $1.3 billion, and Imaging revenues grew 7.4% to $2.3 billion. Patient Care Solutions was the lone decliner, with revenues down 6.5% to $704 million.
GEHC noted it closed its $2.3 billion acquisition of Intelerad during the quarter, which the company said will advance its cloud-enabled enterprise imaging capabilities. Among other recent highlights, the firm received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its View diagnostic viewer and its Photonova Spectra photon-counting CT system.
